About MediciNova Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://medicinova.com/
Frequently Asked Questions
What is the 52-week range for MNOV?
The 52-week high is $3.8999 and the 52-week low is $1.168.
What is the P/E ratio for MNOV?
The P/E ratio data is currently unavailable.
What is the dividend yield for MNOV?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -26.51%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1168.20%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.55.
Analyst Recommendation Trends
Wall Street analyst consensus for MNOV over the last few months:
Latest MNOV News
Let's take a look at the stocks that are in motion in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus. The exploratory study highlighted improvements in cardiovascular lipid markers, alongside positive trends in liver fat reduction and body weight loss. Phase 2 Trial Design And Efficacy Findings The MN-001-NATG-202
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
MediciNova Inc (NASDAQ:MNOV) shares fell 14. 7% in premarket trading on Monday after the company reported topline results from a Phase 2 clinical trial evaluating tipelukast, or MN-001, in patients with nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus.
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
Investing.com -- MediciNova Inc (NASDAQ:MNOV) shares fell 14.7% in premarket trading Monday following mixed results from a Phase 2 clinical trial evaluating tipelukast (MN-001) for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fatLA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) stock moved
MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant
Study OverviewMN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of MN-001 in 40 patients with NAFLD and hypertriglyceridemia associated
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 participants were randomized to tw
MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis
A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in the Open-Label
Unusual volume stocks in Tuesday's session
Unusual volume stocks are being observed in Tuesday's session.
Unusual volume stocks in Monday's session
Unusual volume stocks in Monday's session
Unusual volume stocks in Friday's session
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies (NASDAQ:BIAF) shares
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares increased by
MediciNova to Participate in Two Investor Conferences in September
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will participate in two investor conferences during September. H.C. Wainwright 28th Annual Global Investment Conference, September 14-16 at the Lotte
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-25 | 3D Investment Partners Pte. Ltd. | -640,000 | $2.7 | $1,728,000 |
| 2026-06-23 | Nagao Hideki | +44,500 | - | - |
| 2026-06-23 | Lemerond Nicole | +44,500 | - | - |
| 2026-06-23 | BEAVER CAROLYN | +44,500 | - | - |
| 2026-01-16 | Matsuda Kazuko | +350,000 | - | - |
| 2026-01-16 | IWAKI YUICHI | +450,000 | - | - |